Literature

BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China


BeiGene Ltd announced today that the first patient was dosed in a Phase 3 clinical trial of tislelizumab, an investigational…

Read More

Starving cancer cells to death


These findings suggest that periodic fasting may improve patient outcome in the context of cisplatin-resistant cancers by depriving the cells…

Read More

Poziotinib as a Clinically Active Inhibitor of EGFR and HER2 exon 20 mutations


A new TKI on horizon for metastatic NSCLC

Roche presents biomarker test to identify NSCLC responders to Tecentriq


Researchers at Roche's US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used…

Read More

Reducing NOVA1 helps prevent tumour growth in lung cancer


Researchers have identified a gene that when inhibited, reduced human non-small cell lung cancer tumours from growing…

https://www.drugtargetreview.com/news/34089/reducing-nova1-lung-cancer/

Read More